Efficacy of trabectedin for advanced sarcomas in clinical trials ve...
- PubMed - NCBI
The NCBI web site requires JavaScript to function.
FormatSummarySummary (text)AbstractAbstract (text)MEDLINEXMLPMID ListApplyChoose DestinationFileClipboardCollectionsE-mailOrderMy BibliographyCitation managerFormatSummary (text)Abstract (text)MEDLINEXMLPMID ListCSVCreate File1 selected item: FormatSummarySummary (text)AbstractAbstract (text)MEDLINEXMLPMID ListMeSH and Other DataE-mailSubjectAdditional textE-mailAdd to ClipboardAdd to CollectionsOrder articlesAdd to My BibliographyGenerate a file for use with external citation management software.Create File
):113-9. doi: 10.1097/CAD.0b013eb.Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.1, , , , , , , , , , , , , , , .1Department of Medicine, Unité INSERM, Centre Léon Bérard, Lyon, France. fayette@lyon.fnclcc.frAbstractTrabectedin was recently approved for patients failing doxorubicin, the standard treatment for advanced/metastatic sarcoma. This retrospective study aimed to compare trabectedin efficacy between compassionate use in unselected patients and clinical trials. From May 1999 to January 2006, 92 patients were treated at the Centre Léon Bérard, either in phase II studies or on a named patient compassionate basis. All cases were retrospectively analyzed to assess trabectedin efficacy in terms of response, progression-free, and overall survival.The objective response rate was 10% (N=9): 4% (N=2) for patients treated in compassionate use program and 16% (N=7) for those in clinical trials (P=0.18); 26 (28%) patients had stable disease for at least 6 months, 11 (23%) in the compassionate group and 15 (33%) in clinical trials. Median progression-free and overall survivals were, respectively, 2.2 [95% confidence interval (CI): 1.9-3.6] and 8.9 (95% CI: 6.4-14.2) months for all patients, 2.3 (95% CI: 1.9-4.3) and 10.4 (95% CI: 6.9-24.2) months for patients in clinical trials and 1.8 (95% CI: 1.4-3.4) and 6.4 (95% CI: 3.3-14.2) months for patients under compassionate treatment. In this retrospective analysis, the reported grade 3-4 toxicities were increased transaminase (34 patients, 37%) and neutropenia (38 42%). Higher efficacy was observed in phase II studies than with compassionate treatment, but no significant difference remained after adjustment in multivariate analysis for performance status, a well-established prognosis factor. The safety and tolerability of trabectedin shown in clinical trials is confirmed for patients in real-life situation treated in compassionate use programs, but its benefit is higher for patients with performance status 0-1.PMID:
[PubMed - indexed for MEDLINE]
Publication TypesMeSH TermsSubstancesFull Text SourcesOther Literature SourcesMedical
Supplemental Content
External link. Please review our .索拉菲尼在甲状腺癌治疗中的应用_百度文库
两大类热门资源免费畅读
续费一年阅读会员，立省24元！
评价文档：
2页¥3.002页¥3.005页免费2页¥1.002页¥1.00 7页¥3.002页¥3.005页¥3.001页免费1页免费
喜欢此文档的还喜欢22页7下载券
索拉菲尼在甲状腺癌治疗中的应用|
把文档贴到Blog、BBS或个人站等：
普通尺寸(450*500pix)
较大尺寸(630*500pix)
你可能喜欢}